<DOC>
	<DOCNO>NCT00212784</DOCNO>
	<brief_summary>The primary feature schizophrenia schizoaffective disorder characterize positive ( inability think clearly distinguish reality fantasy ) negative symptom ( reduction absence normal behavior emotion ) . Other symptom include reduced ability recall learn information , difficulty problem solve maintain productive employment . Asenapine investigational drug may help correct characteristic schizophrenia alter inbalance brain hormone dopamine serotonin . This 12-month trial test efficacy safety asenapine use active comparator ( olanzapine ) treatment patient schizophrenia . Patients complete 12-month trial option continue drug treatment code 12-month trial unblinded .</brief_summary>
	<brief_title>Efficacy Safety Asenapine Using Active Control Subjects With Schizophrenia Schizoaffective Disorder ( 25517 ) ( P05935 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Asenapine</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Subject schizophrenia schizoaffective disorder . Subject must sign write informed consent . Have uncontrolled , unstable , clinically significant medical condition . Have psychiatric disorder schizophrenia primary diagnosis include depression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>